You're missing the key value proposition of what FebriDx is providing - rapid point of care diagnostics
WITHOUT the need for expensive assay machine platforms to interpret results. In the MeMed example (one of many), the immunoassay platform being MeMed Key.
FebriDx is the next innovative step in diagnostics IMO, so wouldn't call diagnostics requiring machine platforms as direct competitors, rather the current and soon-to-be antiquated diagnostics model for specific use cases, such as FebriDx for bacterial vs viral infections at local GP.
@danhoff - yes it's
POSITIVE for Lumos, especially tipping signs of growth. I'd have thought they would be more sensitive around mentioning key customers, but hey, information is good for all. Aside from growth, which I can assume is pre-sales production (tick), AT1's Pascal product is essentially the husk of the FebriDx kit. If you read a bit further down, their OEM sales was $321k against 151k in Pascal units sold. Basically, we can assume a large portion of FebriDx COGS is
ONLY AUD
$2 per unit (tick tick). That unit cost also being for external manufacture via AT1, and not produced internally once at scale for lower unit cost. In the US, FebriDx would be sold at USD $23 at hospital (see 2020 assumption
here). Ie. high margin (tick tick tick)
Lower cost to patient, no need for expensive machine platforms meaning higher penetration in hospitals and GPs, and high margin for us...
All expressly my opinion only. Please do your own research.
GLTAH.
(20min delay)